Gene expression predicts chemotherapy response in advanced breast cancer
Carol Lovegrove
This article has no abstract so we have provided the first paragraph of the full text.
Studies have shown that DNA microassay-based gene expression profiling of tumor tissue gives prognostic and predictive information that cannot be provided by traditional methods. Recent work using real time reverse transcription polymerase chain reaction (RT-PCR) to quantify gene expression in formalin-fixed, paraffin-embedded (FPE) tumor specimens identified a 21-gene Recurrence Score (RS) assay, which quantifies the risk of distant recurrence in breast cancer patients treated with adjuvant tamoxifen. Using these methods, Gianni and colleagues examined the correlation between RS and pathological complete response (pCR) to preoperative chemotherapy (paclitaxel and doxorubicin), and analyzed the association between gene expression and pCR.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.